Recent Quotes (30 days)

You have no recent quotes
chg | %

Cascadian Therapeutics Inc (USA)  

(Public, NASDAQ:CASC)   Watch this stock  
Find more results for Nasdaq:ONTY
3.99
-0.06 (-1.48%)
After Hours: 3.99 0.00 (0.00%)
Jul 25, 5:10PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.99 - 4.09
52 week 3.18 - 10.98
Open 4.08
Vol / Avg. 189,641.00/478,581.00
Mkt cap 197.92M
P/E     -
Div/yield     -
EPS -2.85
Shares 49.24M
Beta 2.30
Inst. own 84%
Jun 6, 2017
Cascadian Therapeutics Inc at Jefferies Healthcare Conference
May 11, 2017
Q1 2017 Cascadian Therapeutics Inc Earnings Release (Estimated)
May 9, 2017
Q1 2017 Cascadian Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -38.04% -64.17%
Return on average equity -43.95% -76.28%
Employees 57 -
CDP Score - -

Address

2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Officers and directors

Christopher S. Henney Ph.D. Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Scott D. Myers President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 51
Bio & Compensation  - Reuters
Gary W. Christianson Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Robert W. Azelby Director
Age: 49
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 57
Bio & Compensation  - Reuters
Ted W. Love M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Daniel Keith Spiegelman Independent Director
Age: 58
Bio & Compensation  - Reuters